All News
Causes of Death in Lupus
The California Lupus Surveillance Project has longitudinally followed included systemic lupus erythematosus (SLE) cases and shown that overall, the leading cause of death was cardiovascular disease (CVD), followed by rheumatic disease and hematologic/oncologic conditions.
Read Article
IL-17 Switching Works in Psoriatic Disease
Analysis of data from a Czech nationwide registry of psoriatic patients receiving biologic or targeted therapies (BIOREP) has shown a high success rate when switching between specific IL-17 inhibitors.
Read Article
COVID-19 Arthropathy and Myalgia
An online survey of random COVID-19 infected persons shows that arthralgia and myalgia are common consequences to COVID-19 infection.
https://t.co/TbJvTRfsvk https://t.co/yuLN5p5ZAn
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr. Alfonse Masi donates $1.2 Million to establish the Masi endowed chair in Medicine at the University of Illinois College of Medicine, Peoria. Dr. Masi is a giant clinician, researcher, epidemiologist in Rheum w/ > 220 Pubs & Yrs service to the ACR https://t.co/MbCFVZyNs1 https://t.co/LQ9D0ypA53
Links:
Dr. John Cush RheumNow ( View Tweet)
2022 Lasker Award Winners
Widely regarded as America’s top biomedical research prize since its creation more than 75 years ago by Mary and Albert Lasker, the Lasker Awards carry an honorarium of $250,000 for each category.
https://t.co/wBIGMR6lH7 https://t.co/t9HUECimys
Links:
Dr. John Cush RheumNow ( View Tweet)
Opioid Crisis Costs USA $1.5 Trillion
Reuters has reported the results of a Congressional report showing the economic toll of the opioid addiction and overdose crisis on the United States reached nearly $1.5 trillion in 2020 alone and is likely to grow.
https://t.co/Fwk6jDdtiD https://t.co/91d26iEZts
Links:
Dr. John Cush RheumNow ( View Tweet)
This week it's the great and not-so-great on gout, chondrocalcinosis, osteoporosis and misdiagnosis. We are good at many of those things - what's not so great? Let's review the news and journal reports from the past week on RheumNow.
https://t.co/30Ih3xj22t https://t.co/YznOuGg5B2
Links:
Dr. John Cush RheumNow ( View Tweet)
2 open-label reports of JAK inhibitors in Systemic sclerosis (SSc) - 59 SSc pts: significant decr in mRSS in 88%. 28/29 w/ ILD had no progression. Overall responses better in treatment naïve SSc patients. 20% had side-effects. More studies needed https://t.co/PPAHocDWBj https://t.co/hZDGOF6r9k
Links:
Dr. John Cush RheumNow ( View Tweet)
Five Senses of Medicine - nice graphic download on Clinical Skils (from Annals of Internal Medicine) https://t.co/8RNpqovtVP https://t.co/FkOSZCtv8c
Links:
Dr. John Cush RheumNow ( View Tweet)
Efficacy and Safety of JAK Inhibitors in Psoriatic Disease
There is a growing body of evidence demonstrating efficacy and safety of JAK inhibitors in patients with moderate-to-severe PSO and PsA, according to a systematic review in BMC Rheumatology.
https://t.co/8Y4V1jUlzo https://t.co/eFqknUfGat
Links:
Dr. John Cush RheumNow ( View Tweet)
Study of 67 OA TKR pts looked for CPPD - defined as "appears as linear/punctate opacities w/in cartilage, synovium, Jt capsule or tendons/entheses". Xrays had specificity of 92%, sensitivity 54%, PPV 88%, NPV 66% (needs to be distinguished from BCP) https://t.co/i0ZagblzPZ https://t.co/CiusWPzjrK
Links:
Dr. John Cush RheumNow ( View Tweet)
Are We Overcautious With TNF Inhibitors in Pregnancy?
What may seem like a prudent approach to treatment of IBD in pregnant women actually represents an overabundance of caution, suggested researchers who found no increased risk from TNF inhibitors.
https://t.co/gYqJDBHTBQ https://t.co/aBXl49wJzM
Links:
Dr. John Cush RheumNow ( View Tweet)
Long term results of KEEPsAKE 1 and 2, RCTS of SKYRIZI (IL-23 inhibitor) in active #PsA pts were presented at EADV mtg in Milan. At wk 100, showed more than half of PsA patients achieved PASI 90 & ACR 20 responses. https://t.co/ZJsR0R5WNW https://t.co/2GU5aaSwDZ
Links:
Dr. John Cush RheumNow ( View Tweet)
IL-18 is a proinflammatory cytokine involved in innate &adaptive immune responses. IL-18 is a key mediator in autoinflammatory diseases, MAS, Still’s disease. Serum IL-18 levels may be useful in diagnosis and monitoring of disease activity https://t.co/P8ecLAtNx5 https://t.co/3mo1vcYKUr
Links:
Dr. John Cush RheumNow ( View Tweet)
Cancer Risk with Scleroderma
Spanish Scleroderma Registry examined a large cohort of systemic sclerosis (SSc) patients showing an increased cancer risk, especially breast, lung, hematologic and colorectal cancer.
https://t.co/2sCI6AejRn https://t.co/estX9D39tZ
Links:
Dr. John Cush RheumNow ( View Tweet)
Is PMR the Next Indication for Tocilizumab?
About half of patients with steroid-dependent PMR were able to get off steroids altogether when they were started on tocilizumab (Actemra) infusions, a randomized phase III trial showed.
https://t.co/fe8d6LNMOh https://t.co/RLhnaEPOVK
Links:
Dr. John Cush RheumNow ( View Tweet)
This week it's the great and not-so-great on gout, chondrocalcinosis, osteoporosis and misdiagnosis. We are good at many of those things - what's not so great? Let's review the news and journal reports from the past week on RheumNow.
https://t.co/8hICpPVC8b https://t.co/GDHaBb6fFC
Links:
Dr. John Cush RheumNow ( View Tweet)
A Rheum & Derm Conversation on Treating PsA and Moderate-to-Severe PsO
Sponsored by Lilly USA
Listen to Drs Mease and Armstrong discuss a multidisciplinary approach and important considerations when treating patients with joint and skin concerns. https://t.co/ZAVA83QNa3
Links:
Dr. John Cush RheumNow ( View Tweet)
2 open-label reports of JAK inhibitors in Systemic sclerosis (SSc) - 59 SSc pts: significant decr in mRSS in 88%. 28/29 w/ ILD had no progression. Overall responses better in treatment naïve SSc patients. 20% had side-effects. More studies needed https://t.co/JtaBxVjoak https://t.co/k34P6SjC6L
Links:
Dr. John Cush RheumNow ( View Tweet)
Proposed modified SRI (SLE Responder Index) - Reduction in SLEDAI-2K ≥4 (w/ no worsening in MD global (PGA) ≥0.3). mSRI responders had signif lower Dz activity & pred dose, More LLDAS & remission, less damage accrual (p<0.001) https://t.co/lwsZpnRz3l https://t.co/V7pDYswM7b
Links:
Dr. John Cush RheumNow ( View Tweet)